European Medicines Agency (EMA) moves to Amsterdam South
AIMMS Director Nico Vermeulen is delighted with the news: "this will have a positive impact on pharmaceutical research and education in our country".
11/22/2017 | 1:17 PM
Among other things, EMA is involved in the evaluation and registration of new medicines. Almost 900 people are working at this agency and the organization has a budget of over 300 million Euro.
Apart from the prestige and economic benefits for the region of Amsterdam and the Netherlands, the move (in 2019) has a positive impact on pharmaceutical research and education in our country, says Nico Vermeulen (Director of AIMMS). More specifically, it is for example a very positive outcome for MSc-programmes like Drug Discovery & Safety (DDS), BioInformatics and Systems Biology (BSB) and Science Business and Innovation (SBI). On the shorter and longer term, it will certainly also provide new opportunities for our PhD students and for pharmaceutical and life sciences oriented research.
The move of the European Council was decided upon in Brussels. Ultimately, it was a lottery between Milan and Amsterdam. In total, nineteen European countries made a bid to house this EC agency, which is currently housed in London, but is forced to move due to Brexit.